David J Taber1,2, Mulugeta G Gebregziabher3, Titte R Srinivas4, Kenneth D Chavin1, Prabhakar K Baliga1, Leonard E Egede5. 1. Division of Transplant Surgery, College of Medicine, Medical University of South Carolina, Charleston, South Carolina. 2. Department of Pharmacy, Ralph H. Johnson VAMC, Charleston, South Carolina. 3. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, South Carolina. 4. Division of Transplant, Nephrology, College of Medicine, Medical University of South Carolina, Charleston, South Carolina. 5. Veterans Affairs HSR&D Health Equity and Rural Outreach Innovation Center (HEROIC), Ralph H. Johnson VAMC, Charleston, South Carolina.
Abstract
STUDY OBJECTIVE: To determine the effect of tacrolimus trough concentrations on clinical outcomes in kidney transplantation, while assessing if African-American (AA) race modifies these associations. DESIGN: Retrospective longitudinal cohort study of solitary adult kidney transplants. SETTING: Large tertiary care transplant center. PATIENTS: Adult solitary kidney transplant recipients (n=1078) who were AA (n=567) or non-AA (n=511). EXPOSURE: Mean and regressed slope of tacrolimus trough concentrations. Subtherapeutic concentrations were lower than 8 ng/ml. MEASUREMENTS AND MAIN RESULTS: AA patients were 1.7 times less likely than non-AA patients to achieve therapeutic tacrolimus concentrations (8 ng/ml or higher) during the first year after kidney transplant (35% vs 21%, respectively, p<0.001). AAs not achieving therapeutic concentrations were 2.4 times more likely to have acute cellular rejection (ACR) as compared with AAs achieving therapeutic concentrations (20.8% vs 8.5%, respectively, p<0.01) and 2.5 times more likely to have antibody-mediated rejection (AMR; 8.9% vs 3.6%, respectively, p<0.01). Rates of ACR (8.3% vs 6.7%) and AMR (2.0% vs 0.9% p=0.131) were similar in non-AAs compared across tacrolimus concentration groups. Multivariate modeling confirmed these findings and demonstrated that AAs with low tacrolimus exposure experienced a mild protective effect for the development of interstitial fibrosis/tubular atrophy (IF/TA; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.47-1.32) with the opposite demonstrated in non-AAs (HR 2.2, 95% CI 0.90-5.1). CONCLUSION: In contradistinction to non-AAs, AAs who achieve therapeutic tacrolimus concentrations have substantially lower acute rejection rates but are at risk of developing IF/TA. These findings may reflect modifiable time-dependent racial differences in the concentration-effect relationship of tacrolimus. Achievement of therapeutic tacrolimus trough concentrations, potentially through genotyping and more aggressive dosing and monitoring, is essential to minimize the risk of acute rejection in AA kidney transplant recipients.
STUDY OBJECTIVE: To determine the effect of tacrolimus trough concentrations on clinical outcomes in kidney transplantation, while assessing if African-American (AA) race modifies these associations. DESIGN: Retrospective longitudinal cohort study of solitary adult kidney transplants. SETTING: Large tertiary care transplant center. PATIENTS: Adult solitary kidney transplant recipients (n=1078) who were AA (n=567) or non-AA (n=511). EXPOSURE: Mean and regressed slope of tacrolimus trough concentrations. Subtherapeutic concentrations were lower than 8 ng/ml. MEASUREMENTS AND MAIN RESULTS: AA patients were 1.7 times less likely than non-AA patients to achieve therapeutic tacrolimus concentrations (8 ng/ml or higher) during the first year after kidney transplant (35% vs 21%, respectively, p<0.001). AAs not achieving therapeutic concentrations were 2.4 times more likely to have acute cellular rejection (ACR) as compared with AAs achieving therapeutic concentrations (20.8% vs 8.5%, respectively, p<0.01) and 2.5 times more likely to have antibody-mediated rejection (AMR; 8.9% vs 3.6%, respectively, p<0.01). Rates of ACR (8.3% vs 6.7%) and AMR (2.0% vs 0.9% p=0.131) were similar in non-AAs compared across tacrolimus concentration groups. Multivariate modeling confirmed these findings and demonstrated that AAs with low tacrolimus exposure experienced a mild protective effect for the development of interstitial fibrosis/tubular atrophy (IF/TA; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.47-1.32) with the opposite demonstrated in non-AAs (HR 2.2, 95% CI 0.90-5.1). CONCLUSION: In contradistinction to non-AAs, AAs who achieve therapeutic tacrolimus concentrations have substantially lower acute rejection rates but are at risk of developing IF/TA. These findings may reflect modifiable time-dependent racial differences in the concentration-effect relationship of tacrolimus. Achievement of therapeutic tacrolimus trough concentrations, potentially through genotyping and more aggressive dosing and monitoring, is essential to minimize the risk of acute rejection in AA kidney transplant recipients.
Authors: L M Mancinelli; L Frassetto; L C Floren; D Dressler; S Carrier; I Bekersky; L Z Benet; U Christians Journal: Clin Pharmacol Ther Date: 2001-01 Impact factor: 6.875
Authors: D O McDaniel; W H Barber; C Nguyan; S W Rhodes; W L May; L S McDaniel; P J S Vig; L L Jemeson; D E Butkus Journal: Transpl Immunol Date: 2003 Jan-Mar Impact factor: 1.708
Authors: A J Matas; J M Smith; M A Skeans; K E Lamb; S K Gustafson; C J Samana; D E Stewart; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2013-01 Impact factor: 8.086
Authors: R Bouamar; N Shuker; D A Hesselink; W Weimar; H Ekberg; B Kaplan; C Bernasconi; T van Gelder Journal: Am J Transplant Date: 2013-03-08 Impact factor: 8.086
Authors: Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder Journal: Clin Pharmacokinet Date: 2014-02 Impact factor: 6.447
Authors: David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede Journal: Hypertension Date: 2016-07-11 Impact factor: 10.190
Authors: W S Oetting; D P Schladt; W Guan; M B Miller; R P Remmel; C Dorr; K Sanghavi; R B Mannon; B Herrera; A J Matas; D R Salomon; P-Y Kwok; B J Keating; A K Israni; P A Jacobson Journal: Am J Transplant Date: 2015-10-20 Impact factor: 8.086
Authors: David J Taber; Kelly J Hunt; Mulugeta Gebregziabher; Titte Srinivas; Kenneth D Chavin; Prabhakar K Baliga; Leonard E Egede Journal: Clin J Am Soc Nephrol Date: 2016-12-15 Impact factor: 8.237
Authors: Jennifer M Kwan; Zahraa Hajjiri; Yi Fan Chen; Ahmed Metwally; David L Perkins; Patricia W Finn Journal: J Racial Ethn Health Disparities Date: 2017-12-21
Authors: David J Taber; Zemin Su; James N Fleming; John W McGillicuddy; Maria A Posadas-Salas; Frank A Treiber; Derek Dubay; Titte R Srinivas; Patrick D Mauldin; William P Moran; Prabhakar K Baliga Journal: Transplantation Date: 2017-12 Impact factor: 4.939
Authors: Dana R Pierce; Patricia West-Thielke; Zahraa Hajjiri; Sujata Gaitonde; Ivo Tzvetanov; Enrico Benedetti; Alicia B Lichvar Journal: Transplant Direct Date: 2021-05-18
Authors: Joseph Bayne; Michael Francke; Elaine Ma; Geoffrey A Rubin; Uma Mahesh R Avula; Haajra Baksh; Raymond Givens; Elaine Y Wan Journal: J Racial Ethn Health Disparities Date: 2020-10-28